Cytokine has been used as an immune stimulator and administered to patients for a treatment of cancer. Interleukin-12 (IL-12) is a potent cytokine which acts through a variety of functions including i n t e r f e r o n -γ production and cytotoxic T-cell activation. Considering the toxicity of high dose systemic IL-12 administration into human, local administration of low dose IL-12 can be a more efficient strategy. In ex vivo therapy, human dermal fibroblast has been considered as a useful vehicle for transferring genes. Here we show that human dermal fibroblast transduced with retrovirus containing IL-12 gene can be manipulated to produce reasonable amount of IL-12 protein. Human dermal fibroblast was isolated from freshly harvested skin specimens by collagenase digestion, grown in primary cultures, and transduced with a retroviral vector containing genes for human IL-12 and a selectable marker Neo R . Following selection in G418, IL-12 producing fibroblasts were tested for secreted IL-12 level by ELISA. Six specimens of human skin were processed to obtain fibroblasts. ELISA results show that 40-150 units of IL-12 was produced for 24 h from 1 1 0 6 cells of transduced and selected fibroblast cultures. The primary cultures were maintained for up to nine passages about 108 days. The mean ± overall time for obtaining enough number of cells was 49 ± 2 days. The fibroblasts continued to produce IL-12 in culture for 90 days. These preliminary results can be used for the design of ex vivo gene therapy clinical trial using human dermal fibroblast.
Introduction
Recently, gene therapy appears to be a new way of treatment for cancer and many other genetic disorders. For most patients with disseminated and/or locally faradvanced cancer, conventional therapy can not be an efficient therapeutic modality. Murine therapeutic studies (Nastala et al., 1994; Tahara et al., 1994) demonstrated that interleukin-12 (IL-12) induces clinically significant tumor regression. This and many other reports imply that cytokine microenvironment at the tumor site may determine the outcome of the immune response (Tepper et al., 1989; Fearson et al., 1990; Gansbacher et al., 1990) . Among those cytokines, IL-12 exerts a variety of biological effects on human T and NK cells which includes IFN-γ production from peripheral blood lymphocytes and augmentation of allogeneic CTLresponses in combination with IL-2 (Kobayashi et al. , 1989; Stern et al., 1990; Chan et al., 1991; Gately e t a l., 1991) . The fact that IL-12 is produced only by professional antigen presenting cells like B cells or macrophages implies strongly that local administration of IL-12 at the tumor site may be an ideal strategy to elicit endogenous immune responses. With this method high concentration of IL-12 can be given locally without evolving systemic toxicity. Human skin fibroblast can be used as an efficient tool to transfer a gene ex vivo and finally to patient's tumor site for paracrine cytokine secretion. Human dermal fibroblast is a dividing cell, therefore, it is relatively easy to culture, transduce and select, and produce a relevant level of cytokine after gene transfer. The present study was designed to find out the level of individual variation in the IL-12 production after the culture, transduction, and selection of fibroblast as a preclinical study.
Materials and Methods

Biopsies
Six skin samples measuring 20 cm 2 were obtained during surgical procedures performed on human adults.
Preparation of fibroblasts
An ellipse of skin measure 10 cm by 2 cm is resected from a convenient location in a sterile fashion. The skin was transferred to laboratory and cleared of fat and epidermal layer. After dividing into 1-2 mm diameter pieces, the skin was incubated with 0.5% (w/v) collagenase (Sigma Chemical, St. Louis, MO ) and plated in flasks containing sterile culture medium and 10% human AB serum. Culture medium contained fibroblast basal medium with 5 μg/ml human insulin (Life Technologies, Gaithersburg, MD), 1 ng/ml human bFGF (Clonetics, San Diego, CA), 50 μg/ml gentamycin, and 250 ng/ml amphotericin B. After first passage, fibroblasts were transduced with TFG-hIL-12-Neo retroviral vector. Protamine sulfate (Sigma Chemical) was added as carrier at a concentration of 5 μg/ml. The stably transfected fibroblasts were grown in medium containing appropriate amount (0.05-0.1 mg/ml) of a neomycin analog, G418 (Geneticin, Life Technologies). All cultures were tested periodically to ensure the absence of mycoplasma contamination.
Viral vector supernatants
Retroviral vector containing genes of IL-12 and neomycine phosphotransferase (TFG-hIL-12-Neo retroviral vector) was obtained from M. Lotze of University of Pittsburgh (Zitvogel et al., 1994) .
Transduction and growth of fibroblasts
Proliferating fibroblasts were transduced at a multiplicity of infection of 2 with the retroviral vector containing the genes for human IL-12 and neomycin phosphotransferase (N e o R ). Transduction was performed for 2 h at 37˚C in 5% CO 2 incubator. Forty-eight hours after transduction, they were exposed to the selective pressure of 0.05-0.2 mg/ml of G418.
IL-12 detection
IL-12 in culture supernatants was measured using an ELISA kit purchased from R & D Systems (St. Louis, MO). Culture medium of fibroblasts was collected periodically as described in Figure 3 . IL-12 levels were expressed as ng/24 h per 1 10 6 fibroblasts. 
PCR for IL-12, neo and env
Reverse transcription (RT)-PCR for IL-12
Expression of IL-12 mRNA in transduced fibroblasts was confirmed using RT-PCR. mRNA was extracted from approximately 1 1 0 7 transduced cells using a s i n g l e step RNA extraction methods with TRIzol (Gibco BRL, Gaithersburg, MD). RT-PCR codition was the same as suggested by manufacturer (Perkin Elmer). The sets o f 5'and 3' primers for PCR were 5
'-GGTATCACCTGGACC-T T G G A C C A G A G C-3' and 5'-G C T G C A A G T T G T T G G G T G G -GTCAGGTTTG-3' for p40 subunit of IL-12 and 5'-ATGAT-T G A A C A A G A T G G A T T G C A C-3' and 5'-T T C G T C C A G A T C A -
TCCTGATCGAC-3' for neo. The expected length of PCR product is 540 and 450 bp, respectively.
Results
Culture of fibroblasts
Primary fibroblasts has been reported to show higher growth rate in suspension culture comparing to the conventional explant culture (Veelken et al., 1994) . As shown in Table 1 , there were differences in growth rate of individual specimen. Specimen-1 and 2 were growing very well, while specimen-4 stopped growing around day 70 after delayed growth and specimen-5 showed considerably low growth rate comparing to other ones. As demonstrated by Veelken et al. (1994) , most of the cultures eventually underwent a retardation of proliferation. And the overall cell number that could be reached until retardation of growth correlated with the age of donor (Table 1) . 150 ± 10 40 ± 12 100 ± 7 66 ± 2 40 ± 5 67 ± 5 Table 1 . Amount of produced IL-12 after transduction and selection of human dermal fibroblast in culture.
Transduction of a TFG-hIL-12-Neo retrovirus
into human fibroblast
To assess the transfer of the human IL-12 gene into the fibroblast, PCR was performed using genomic DNAs from fibroblasts before and after transduction. Successfully transduced fibroblasts gave amplified products of 540 bp with primers for IL-12 and 490 bp with primers for n e o gene, as shown in Figure 1 . Transduced fibroblasts didn't show positive band of 712 bp with retrovirus env gene primers after transduction.
IL-12 mRNA and protein are expressed in transduced cells
To generate fibroblasts secreting IL-12, retroviral vectors expressing p35 and p40 subunit of IL-12 and neomycin phosphotransferase (crip-TFG-hIL-12-Neo) were given to transduce human fibroblasts. Following transduction, selection in G418, and expansion of G418 resistant cells, the supernatant was tested for IL-12 secretion by ELISA. RT-PCR of transduced cells showed expression of both IL-12 p40 subunit and neomycine phosphotransferase in transfected fibroblast but expression of neither mRNA was detected in untransfected one (Figure 2 ).
Interleukin-12 production profiles of transduced fibroblasts
After selection with G418, non-transduced cells were dying while transduced fibroblasts were selectively growing very well (Figure 3 ). IL-12 production profile of specimen-2 fibroblasts was shown in Figure 4 . All other specimens had similar profiles of IL-12 production and none of six normal fibroblasts secreted detectable IL-12 production. As shown in the figure, the fibroblasts number continued to increase after culture until G418 selection began around day 15, day 32 and day 47. Then, during G418 selection, the growth rate of fibroblasts was reduced dramatically until the end of each selection step (day 25, day 37 and day 52). After the selection was completed around day 52, fibroblasts number began to increase again. The selection of transduced fibroblasts coincides with the increase in IL-12 production as shown in Figure 4 . Although there was some differences among individual specimens, IL-12 was produced in a reasonable amount (40-150 ng/24 h/10 6 cells) in all specimens. 
A B Discussion
Retroviral vector used here has three cistrons, p35, p40 subunits for IL-12 and n e o as a selection marker (Zitvogel et al., 1994) . Figure 1 shows that all these genes are integrated stably to the fibroblasts. Duration of cytokine secretion in vitro was determined after transfection. IL-12 secretion of retrovirally transfected fibroblasts initially increased upto about 70 ng per 1 10 6 cells for 24 h (Figure 4 ) and was measurable for 12 weeks (data not shown). There were some differences in the amount of secreted IL-12 according to individual as shown in Table 1 . The range of IL-12 was between 40 to 150 ng per 1 10 6 cells for 24 h. These amounts are enough for phase I clinical trial which has IL-12 of 10-3,000 ng range for 24 h.
IL-12 induces a considerably increased production of I F N -γ from peripheral blood lymphocytes after slight increase in IL-12 production. Nastala et al . (1994) reported that some animals cured by IL-12 did not have long-term immunity and the anti-tumor effect of IL-12 may include non-T cell-mediated immune reactions. Data published by Voest et al. (1985) can be one of these examples. They suggested that anti-angiogenic effects of IL-12 may account for antitumor activity.
In several clinical situations, transient expression of a therapeutic molecule by genetically modified cells might offer advantages over the application of the recombinant gene product. First, systemic toxicities associated with immunotherapy might be overcome if cytokine expression is localized to the tumor site. Bramson et al. (1996) have reported that IL-12 expression is localized to tumor after injection. They also showed that the virally expressed cytokine is produced at high levels within the tumor and remains localized to the site, indicating that systemic complications due to excess IL-12 in the serum can be overcome. Second, local delivery of cytokines is closer to the natural immune response. Zitvogel et al. (1994) demonstrated that fibroblasts transduced with a retroviral vector expressing IL-12 can be used to treat pre-established tumors in mouse model. They reported that antitumor effects were observed more rapidly when the cells were injected at the tumor site.
IL-12 has been proven as an useful therapeutic agent for cancer gene therapy in a mouse model using retroviral vector . Bramson et al. (1996) have demonstrated that in mouse model using adenoviral system expressing IL-12, the serum IL-12 decline five-fold from day 1 to day 3 whereas the intratumoral IL-12 only began to decline around day 6. All these results indicate that local expression is more effective.
In human, even after lethal irradiation, tumor itself can not be an adequate source for the production of therapeutic molecules. Among many known potential target cell types for gene delivery, like endothelial cells, myoblasts, and hepatocytes (Wilson et al., 1989; Barr et al., 1991; Dhawan et al., 1991) , fibroblasts are chosen because it is easy to culture, transfect with retrovirus and select with G418 (Garver et al., 1987; Palmer e t a l., 1987; Selden et al., 1987; Moullier et al., 1993; Heartlein et al., 1994; Naffakh et al ., 1995) . IL-12 secretion can be maintained in vitro for more than 90 days (data not shown), indicating that stably transfected fibroblasts that secrete sufficient amount of transfected gene product can be useful for cancer gene therapy.
